June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut
Lilly partners with Evox on exosome therapies
Eli Lilly and Co. (NYSE:LLY) entered a collaboration and five-target licensing deal with Oxford-based Evox Therapeutics Ltd. to develop and deliver RNAi and antisense oligonucleotides for neurological disorders using the latter’s DeliverEX platform. Evox, which is responsible for bringing candidates through preclinical proof-of-concept studies, will receive $20 million up front, research funding over three years, and a $10 million convertible bond investment, plus up to $1.2 billion in milestones and tiered royalties up to low double digits.
Alphamab, Sanofi partner to advance breast cancer combo
Jiangsu Alphamab Biopharmaceuticals Co. Ltd., a wholly-owned subsidiary of Alphamab Oncology Ltd. (HKEX:9966) and the Sanofi China unit of Sanofi (Euronext:SAN; NASDAQ:SNY), announced a collaboration to advance clinical studies of KN026 plus Taxotere docetaxel in HER2-positive breast cancer. Sanofi has an exclusivity period to negotiate in-licensing KN026 contingent on undisclosed clinical milestones...